Plant Name: Selaginella doederleinii hieron
Taxonomic Information:
Plant ID: NPO17417
Plant Latin Name: Selaginella doederleinii hieron
Taxonomy Genus: Selaginella
Taxonomy Family: Selaginellaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; | |
| ACHE; | |
| CSNK2A1; | |
| ESR2; | |
| HSD17B1; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.192E-10 | 5.863E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.341E-09 | 3.877E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.197E-08 | 6.515E-05 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.322E-07 | 3.600E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.760E-07 | 3.649E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.746E-07 | 5.875E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.160E-07 | 1.173E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.447E-06 | 1.750E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 4.226E-06 | 4.001E-03 | ACHE, CSNK2A1, CYP19A1, CYP1A1, HSD17B1 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 6.743E-06 | 6.118E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.285E-11 | 1.243E-09 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 7.177E-09 | 1.041E-07 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.807E-07 | 8.514E-06 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.496E-06 | 3.985E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.808E-06 | 4.529E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.602E-04 | 2.224E-03 | CYP1A2, CYP1A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.276E-03 | 9.054E-03 | HSD17B1, CYP1A2, CYP1A1, CYP19A1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.498E-03 | 9.054E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; OPRD1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; OPRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
